东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06887 东阳光药

休市中 07-31 16:08:41

41.820

+1.620

+4.03%

最高41.980	最低38.660	成交量156.43万
今开40.000	昨收40.200	日振幅8.26%
总市值240.47亿	流通市值133.82亿	总股本5.75亿
成交额6,350万	换手率0.49%	流通股本3.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06887","market":"HK","secType":"STK","nameCN":"东阳光药","latestPrice":41.82,"timestamp":1785485321010,"preClose":40.2,"halted":0,"volume":1564253,"delay":0,"changeRate":0.0402985074626865,"floatShares":320000000,"shares":575000000,"eps":0.6385072344430068,"marketStatus":"休市中","change":1.62,"latestTime":"07-31 16:08:41","open":40,"high":41.98,"low":38.66,"amount":63503794,"amplitude":0.082587,"askPrice":41.82,"askSize":4100,"bidPrice":41.8,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":0.6083232560875192,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785720600000},"marketStatusCode":7,"adr":0,"listingDate":1754496000000,"exchange":"SEHK","adjPreClose":40.2,"openAndCloseTimeList":[[1785461400000,1785470400000],[1785474000000,1785484800000]],"volumeRatio":2.003497356426459,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06887","defaultTab":"news","newsList":[{"id":"2655694733","title":"东阳光药甘精胰岛素发运海外，商业化落地打开新空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2655694733","media":"经济参考网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655694733?lang=zh_cn&edition=full","pubTime":"2026-07-31 20:56","pubTimestamp":1785502599,"startTime":"0","endTime":"0","summary":"7月31日，东阳光药发布公告称其自主研发的甘精胰岛素注射液（商品名：Langlara）已启动美国市场商业化发货。首批计划发货总量为115.2万支，将分批次有序发货，预计于2026年8月中下旬完成。本次成品批量出货，为二级市场提供了可量化、可追踪的海外营收增量信号。这也是国内企业成功突破美国胰岛素市场的重要商业化案例。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313828576573.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313828576573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181533841","title":"一周港股牛熊榜 | 海致科技周涨40%问鼎牛榜榜首；清盘人重启股权出售计划，恒大物业周涨23%；伟禄科技暴跌33%，遭大股东减持12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181533841","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181533841?lang=zh_cn&edition=full","pubTime":"2026-07-31 19:35","pubTimestamp":1785497713,"startTime":"0","endTime":"0","summary":"7月全月恒指累升3,003点或13.1%。该股7月21日盘中一度跌33%至111港元，此前7月17日尚报203.60港元。张先生通过其或透过其控制的实体计划于未来6个月增持价值介乎3.0亿港元至6.0亿港元的股份。下一步，计划邀请潜在买方对集团进行尽职调查。出售事项后，美林控股持有7.33亿股股份，占本公司已发行股本总额约50.83%。美林控股进一步告知董事会，据其深知、尽悉及确信，于出售事项前，买方为本公司及其关连人士的独立第三方","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02706","01888","02687","06887","09903","01196","06666","09606","01783","06166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163476810","title":"东阳光药（06887）启动115.2万支甘精胰岛素首批对美商业化发货","url":"https://stock-news.laohu8.com/highlight/detail?id=1163476810","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163476810?lang=zh_cn&edition=full","pubTime":"2026-07-31 18:16","pubTimestamp":1785493012,"startTime":"0","endTime":"0","summary":"2026年7月31日，广东东阳光药业股份有限公司发布自愿性公告称，公司自主研发的甘精胰岛素注射液已正式启动美国市场商业化发货。首批计划发货总量为115.2万支，将分批有序发运，预计于2026年8月中下旬完成。甘精胰岛素为第三代长效胰岛素类似物，原研商品名为Lantus。根据公告，公司与美国合作方已签署不少于1,800万支产品订单，此次为该框架下的首批交付。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655357389","title":"东阳光药(06887.HK)：甘精胰岛素注射液首次美国商业化发货","url":"https://stock-news.laohu8.com/highlight/detail?id=2655357389","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655357389?lang=zh_cn&edition=full","pubTime":"2026-07-31 18:09","pubTimestamp":1785492592,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109049048","title":"张玉帅增持东阳光药150万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1109049048","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109049048?lang=zh_cn&edition=full","pubTime":"2026-07-30 23:56","pubTimestamp":1785426998,"startTime":"0","endTime":"0","summary":"7月30日，东阳光药（06887.HK）披露，公司相关人士张玉帅于2026年7月24日至30日期间，累计购入150万股H股股份，总耗资约5600万港元。此次增持彰显了其对东阳光药未来发展的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872466","title":"东阳光药德谷胰岛素获批上市，公司胰岛素产品增至6款","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872466","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655872466?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:10","pubTimestamp":1785413454,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655740958","title":"东阳光药(06887)：德谷胰岛素注射液获得国家药品监督管理局(NMPA)的上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655740958","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655740958?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:59","pubTimestamp":1785412776,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药 发布公告，集团自主研发的德谷胰岛素注射液正式获得国家药品监督管理局批准上市，涵盖笔芯和预填充注射笔两个规格。在国际化方面，集团自主研发的甘精胰岛素注射液已于2026年4月底获得美国食品药品监督管理局签发的批准信，成为第4款在美国上市的甘精胰岛素产品，同时公司成为首个在美国市场上市甘精胰岛素的中国制药企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655587411","title":"股东张寓帅增持东阳光药(06887)37.75万股 每股作价38.40港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655587411","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655587411?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:45","pubTimestamp":1785411922,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，7月29日，股东张寓帅增持东阳光药(06887)37.75万股，每股作价38.40港元，总金额约为1449.60万港元。增持后最新持股数目约为1.28亿股，持股比例为39.72%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","EWH","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151817555","title":"东阳光药(06887)披露控股股东最新增持动向：7月24日至30日购入145.14万股，耗资约5600万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1151817555","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151817555?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:35","pubTimestamp":1785411331,"startTime":"0","endTime":"0","summary":"本报讯 广东东阳光药业股份有限公司 7月30日发布自愿性公告称，公司控股股东兼非执行董事张寓帅先生已于2026年7月24日至2026年7月30日期间，通过公开市场以约5600万港元的总代价，合计增持公司1,451,400股H股。公告显示，完成本次增持后，张寓帅先生直接及间接合计持有东阳光药295,423,156股股份，占公司已发行股份总数约51.42%。公司董事会表示，张寓帅先生基于对集团长期发展前景和内在价值的信心，将视市场情况择机继续增持公司股份。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655871106","title":"东阳光药(06887.HK)获控股股东张寓帅累计斥资约5600万港元增持145.14万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655871106","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655871106?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:32","pubTimestamp":1785411121,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132711823","title":"东阳光药：张玉帅于2026年7月24日至30日斥资5600万港元购入150万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1132711823","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132711823?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:31","pubTimestamp":1785411071,"startTime":"0","endTime":"0","summary":"东阳光药（Sunshine Pharma）披露，公司重要股东张玉帅先生，在2026年7月24日至30日这一时间段内，累计出手购入了150万股H股股份。此番增持行动，总耗资高达5600万港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655828623","title":"港股异动 | 东阳光药(06887.HK)再涨近7% 甘精胰岛素注射液获FDA批准 控股股东已启动增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2655828623","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655828623?lang=zh_cn&edition=full","pubTime":"2026-07-30 13:58","pubTimestamp":1785391097,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179467116","title":"东阳光药：7月28日回购4.12万股，耗资约140.77万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1179467116","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179467116?lang=zh_cn&edition=full","pubTime":"2026-07-28 18:05","pubTimestamp":1785233152,"startTime":"0","endTime":"0","summary":"东阳光药于2026年7月28日发布公告，公司当日在香港联合交易所回购了4.12万股H股，占当日前已发行股本约0.0129%。本次回购价格介于每股港币33.68元至34.50元，总金额约为140.77万港元。回购完成后，公司已发行股本变更为3.1897484亿股，库藏股数量增至212.83万股，总发行股本仍为3.2110314亿股。本次回购后，公司适用的任何新股发行或再出售库藏股交易的暂止期将持续至2026年8月27日。东阳光药确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药：7月28日回购4.12万股，耗资约140.77万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654079940","title":"港股异动 | 东阳光药(06887)尾盘涨超5% 控股股东拟斥3亿港元至6亿港元增持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2654079940","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654079940?lang=zh_cn&edition=full","pubTime":"2026-07-28 14:59","pubTimestamp":1785221978,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东阳光药尾盘涨超5%，截至发稿，涨4.87%，报35.72港元，成交额1979.07万港元。消息面上，东阳光药近日公告，控股股东兼非执行董事张寓帅拟于未来6个月增持价值3亿至6亿港元的股份。后续张寓帅将通过其或透过其控制的实体根据市场行情酌情增加增持金额。股份增持计划反映张寓帅对集团的长期发展前景及公司的价值具有坚定信心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","06887","VXUS","BK4588","BK4585","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176272543","title":"东阳光药7月27日回购8,600股，耗资约29.09万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176272543","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176272543?lang=zh_cn&edition=full","pubTime":"2026-07-27 20:16","pubTimestamp":1785154578,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年7月27日披露公告，宣布当日于香港联交所回购普通股H股8,600股，约占该公司已发行股本0.0027%。本次回购的每股价格介乎港币32.9至34港元，总金额约为29.09万港元。本次股份购回后，公司已发行股本变更为319,016,040股，库藏股数提升至2,087,100股。据公告，东阳光药于2026年6月18日通过了购回授权，授权购回总数为57,597,844股。本次购回的股份将被继续持作库藏股，东阳光药已确认此次购回过程符合香港联交所证券上市规则及相关法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药7月27日回购8,600股，耗资约29.09万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654993017","title":"东阳光药(06887.HK)7月27日斥资29.09万港元回购8600股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654993017","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654993017?lang=zh_cn&edition=full","pubTime":"2026-07-27 20:02","pubTimestamp":1785153778,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654609683","title":"港股异动 | 东阳光药(06887)涨超4% 近日获控股股东拟增持约3.0亿至6.0亿港元公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2654609683","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654609683?lang=zh_cn&edition=full","pubTime":"2026-07-27 10:47","pubTimestamp":1785120430,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东阳光药涨超4%，截至发稿，涨3.94%，报34.3港元，成交额542.34万港元。张先生通过其或透过其控制的实体计划于未来6个月增持价值介乎3.0亿港元至6.0亿港元的股份。后续张先生将通过其或透过其控制的实体根据市场行情酌情增加增持金额。截至本公告日期，张先生直接及透过其控制的实体间接持有合共2.94亿股股份，占已发行股份约51.11%。董事会认为，股份增持计划反映张先生对集团的长期发展前景及公司的价值具有坚定信心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","BK1191","KCAI","06887","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653101086","title":"东阳光药(06887)7月24日斥资175.3万港元回购5.42万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653101086","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653101086?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:42","pubTimestamp":1784889732,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药(06887)发布公告，该公司于2026年7月24日斥资175.3万港元回购5.42万股股份，每股回购价格为31.9-32.88港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140289529","title":"东阳光药于7月24日回购5.42万股股份，总额约175.30万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1140289529","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140289529?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:42","pubTimestamp":1784889729,"startTime":"0","endTime":"0","summary":"东阳光药于2026年7月24日发布公告，披露公司当日在香港联交所场内回购普通股H股共计5.42万股。每股回购价介乎港币31.90元至32.88元，总涉资1,753,032港元。回购完成后，公司已发行股本由319,078,840股降至319,024,640股，库藏股数相应增至2,078,500股，合计股本总数仍为321,103,140股。公告显示，东阳光药于2026年6月18日获股东大会通过共计57,597,844股的购回授权。截至公告日，公司已根据购回授权累计回购1,400,900股，占购回授权通过当日已发行股本约0.2432%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药于7月24日回购5.42万股股份，总额约175.30万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124272865","title":"东阳光药：7月23日回购3.7万股，耗资约119.66万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124272865","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124272865?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:26","pubTimestamp":1784802384,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年7月23日公告，当日在香港联合交易所回购H股37,000股，占当日回购前公司已发行股本约0.0116%。回购价格区间为每股31.9港元至33港元，合计耗资约119.66万港元。本次回购完成后，公司已发行股本变动至319,078,840股，库藏股则增至2,024,300股。根据公告，购回授权于2026年6月18日获得通过，授权购回股份总数为57,597,844股，截至目前公司已累计回购1,346,700股，占购回授权决议通过当日已发行股本约0.2338%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药：7月23日回购3.7万股，耗资约119.66万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.2673},{"period":"1month","weight":0.0455},{"period":"3month","weight":0.017},{"period":"6month","weight":-0.0178},{"period":"1year","weight":-0.3058},{"period":"ytd","weight":-0.0829}],"compareEarnings":[{"period":"1week","weight":0.0369},{"period":"1month","weight":0.1313},{"period":"3month","weight":0.0042},{"period":"6month","weight":-0.0549},{"period":"1year","weight":0.0449},{"period":"ytd","weight":0.0099}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"广东东阳光药业股份有限公司是一家主要从事药物的研发、生产和商业化的中国公司。该公司专注于创新药，亦涉及改良型新药、仿制药和生物类似药。该公司的抗感染产品包括可威（磷酸奥司他韦），用于治疗流行性感冒（特别是甲型及乙型流行性感冒病毒），东卫恩（磷酸依米他韦），用于治疗丙型肝炎，及主要用于治疗敏感细菌引起的感染的仿制药，即克拉霉素、左氧氟沙星及盐酸莫西沙星。该公司的慢病治疗药物主要专注于治疗糖尿病、高尿酸血症、高血压及胃酸相关疾病，包括胰岛素产品及仿制药。该公司还关注肿瘤治疗领域。","exchange":"SEHK","name":"东阳光药","nameEN":"SUNSHINE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东阳光药(06887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东阳光药,06887,东阳光药股票,东阳光药股票老虎,东阳光药股票老虎国际,东阳光药行情,东阳光药股票行情,东阳光药股价,东阳光药股市,东阳光药股票价格,东阳光药股票交易,东阳光药股票购买,东阳光药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东阳光药(06887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}